ADORA3 and neoplasm: Activation of A3 AR has been correlated with tumour growth inhibition and apoptosis induction (Borea et al., 2015; Baraldi et al., 2012), and A3 AR agonists were found to display anti‐inflammatory and anticancer effects in melanoma, colon and prostate carcinoma disease models (Fishman et al., 2002; Valdés Zurita et al., 2018).